Last reviewed · How we verify
NCT02846376: CPIT-002
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
Phase 1 trial testing Nivolumab in Acute Myeloid Leukemia and Myelodysplastic Syndrome in 8 participants. Terminated before completion.
21 December 2023
Quick facts
| Lead sponsor | Hackensack Meridian Health |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 8 |
| Start date | 8 March 2019 |
| Primary completion | 21 December 2023 |
| Estimated completion | 21 December 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Nivolumab (nivolumab) — full drug profile →
- Ipilimumab — full drug profile →
Conditions studied
- Acute Myeloid Leukemia and Myelodysplastic Syndrome — all drugs for Acute Myeloid Leukemia and Myelodysplastic Syndrome →
Sponsor
Hackensack Meridian Health — full company profile →
Who can join
Adults 18 to 70, any sex, with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to determine the safety and benefit of nivolumab, ipilimumab or the combination of nivolumab with ipilimumab given after bone marrow transplant for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.
Li K, Shi H, Zhang B, Ou X, et al · · 2021 · cited 687× · PMID 34620838 · DOI 10.1038/s41392-021-00670-9 -
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.
Daver N, Alotaibi AS, Bücklein V, Subklewe M. · · 2021 · cited 178× · PMID 33953290 · DOI 10.1038/s41375-021-01253-x -
Recent advances in targeted therapies in acute myeloid leukemia.
Bhansali RS, Pratz KW, Lai C. · · 2023 · cited 151× · PMID 36966300 · DOI 10.1186/s13045-023-01424-6 -
Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis.
Yamashita M, Dellorusso PV, Olson OC, Passegué E. · · 2020 · cited 128× · PMID 32415283 · DOI 10.1038/s41568-020-0260-3 -
Precision therapy for acute myeloid leukemia.
Yang X, Wang J. · · 2018 · cited 109× · PMID 29301553 · DOI 10.1186/s13045-017-0543-7 -
Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity.
Lamble AJ, Lind EF. · · 2018 · cited 95× · PMID 29951373 · DOI 10.3389/fonc.2018.00213 -
Checkpoint inhibitors in hematological malignancies.
Ok CY, Young KH. · · 2017 · cited 93× · PMID 28482851 · DOI 10.1186/s13045-017-0474-3 -
Advances in targeted therapy for acute myeloid leukaemia.
Kayser S, Levis MJ. · · 2018 · cited 88× · PMID 29193012 · DOI 10.1111/bjh.15032
Verify or expand the search:
- PubMed search for NCT02846376
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nivolumab
Trials testing the same drug.
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
- NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
- NCT07420439 — Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · Phase 2 · not yet recruiting
- NCT07510334 — VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma · Phase 2 · not yet recruiting
Other Hackensack Meridian Health trials
Trials by the same sponsor.
- NCT06785402 — Ceftriaxone for Post-Treatment Lyme Disease · Phase 1, PHASE2 · recruiting
- NCT06987708 — Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers · NA · not yet recruiting
- NCT06575894 — Implementing Mental Health Programs Across Communities in Iowa & Indiana for Transformation · NA · not yet recruiting
- NCT07442669 — Utilization of Lung Ultrasound Score in Decision for Minimally Invasive Surfactant Administration · NA · not yet recruiting
- NCT06991166 — OBWELL: Innovative Psychotherapeutic Intervention to Treat Postpartum Depression · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02846376 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hackensack Meridian Health
- Last refreshed: 18 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02846376.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing